Summit Therapeutics (SMMT) P/S ratio
The P/S ratio of Summit Therapeutics (SMMT) was 195.9× at the end of fiscal 2021 (December 31, 2021). That is 48.5% lower than the 380.0× of fiscal 2020. Figures as of 18 Nov 2026, 07:30 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/S ratio, fiscal 2021
- 195.9×
- Change on fiscal 2020
- −48.5%
- Highest on record
- 380.0×fiscal 2020
- Lowest on record
- 0.4×fiscal 2019
- Fiscal years on record
- 32019–2021
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Summit Therapeutics P/S ratio, in more detail
Across the 3 fiscal year-ends on record (2019–2021), the highest was 380.0× in fiscal 2020 and the lowest 0.4× in fiscal 2019.
P/S ratio at each fiscal year-end
Summit Therapeutics P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| 2025 | — | — | $17.49 | — | |
| 2024 | — | — | $17.84 | — | |
| 2023 | — | — | $2.61 | — | |
| 2022 | — | — | $4.25 | $0.00 | |
| 2021 | 195.9× | 48.5% down | $2.69 | $0.01 | |
| 2020 | 380.0× | 94,561.9% up | $4.70 | $0.01 | |
| 2019 | 0.4× | — | $1.33 | $3.31 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
P/S ratio at health care companies of similar size
| Company | P/S ratio |
|---|---|
| BridgeBio Pharma BBIO | 29.8× |
| Glaukos GKOS | 28.4× |
| Encompass Health EHC | 2.3× |
| BrightSpring Health Services BTSG | 1.1× |
| Baxter International BAX | 1.2× |
Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.
Summit Therapeutics, figure by figure
- Summit Therapeutics market cap
- Summit Therapeutics revenue
- Summit Therapeutics earnings
- Summit Therapeutics earnings per share (EPS)
- Summit Therapeutics P/E ratio
- Summit Therapeutics P/B ratio
- Summit Therapeutics free cash flow
- Summit Therapeutics operating margin
- Summit Therapeutics dividend
- Summit Therapeutics shares outstanding
- Summit Therapeutics total debt
- Summit Therapeutics cash on hand
- Summit Therapeutics total assets
- Summit Therapeutics return on equity (ROE)
- Summit Therapeutics return on invested capital (ROIC)
Summit Therapeutics (SMMT) overview: price, valuation and scorecardAll health care companies by market value
Summit Therapeutics P/S ratio: questions and answers
What is Summit Therapeutics's P/S ratio?
The P/S ratio of Summit Therapeutics (SMMT) was 195.9× at the end of fiscal 2021 (December 31, 2021). That is 48.5% lower than the 380.0× of fiscal 2020.
What are the highest and lowest P/S ratio figures on record for Summit Therapeutics?
Across the 3 fiscal year-ends on record (2019–2021), the highest was 380.0× in fiscal 2020 and the lowest 0.4× in fiscal 2019.
How is Summit Therapeutics's P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Summit Therapeutics (SMMT) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/SMMT/ps-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.